Related Experiment Video

Updated: Feb 3, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease

Zobair Younossi1,2, Georgios Papatheodoridis3, Patrice Cacoub4,5

  • 1Department of Medicine, Inova Fairfax Hospital, Falls Church, Virginia.

Journal of Viral Hepatitis
|November 7, 2018
PubMed

Insights

New hepatitis C virus (HCV) treatments offer high cure rates with few side effects. Eliminating HCV infection is possible by 2030, but requires overcoming barriers to screening and treatment.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Public Health

Background:

  • Hepatitis C virus (HCV) infection poses a significant global health burden.
  • Recent advancements have introduced highly effective, pangenotypic, interferon- and ribavirin-free treatment regimens.
  • HCV cure is associated with reduced complications, improved patient outcomes, and long-term cost savings.

Purpose of the Study:

  • To review the comprehensive burden of HCV infection.
  • To evaluate the value and potential for HCV elimination.
  • To identify barriers hindering global HCV eradication efforts.

Main Methods:

  • This study is a comprehensive literature review.
  • It synthesizes evidence on the impact of HCV infection and the benefits of its cure.
  • It analyzes the feasibility of HCV elimination by 2030.

Main Results:

  • Pangenotypic, interferon-free regimens achieve high HCV cure rates with a favorable side effect profile.
  • HCV elimination by 2030 is a realistic goal for some regions with current treatment options.
  • Significant barriers to screening, linkage to care, and treatment persist globally.

Conclusions:

  • Continued global efforts are essential to achieve HCV elimination.
  • National policies must support accessible screening, care linkage, and affordable treatments.
  • Overcoming existing barriers is crucial to realizing the goal of HCV eradication.

Keywords:
clinicaleconomicsextrahepatic manifestationspatient-reported outcomes

More Related Videos

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.1K
Facet-to-facet Linking of Shape-anisotropic Colloidal Cadmium Chalcogenide Nanostructures09:12

Facet-to-facet Linking of Shape-anisotropic Colloidal Cadmium Chalcogenide Nanostructures

Published on: August 10, 2017

8.0K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
280
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
244
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
728
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.5K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
4.5K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.7K